ArticleClinical and experimental immunology2009
Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.
Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.Experimental gerontology · 2018Trial
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo.Scientific reports · 2022Article
- Targeting autophagy in disease: established and new strategies.Autophagy · 2022Article
- Impact of covid-19 on mental health and aging.Saudi journal of biological sciences · 2021Review
- miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN.Translational cancer research · 2021Article
- Distinct effects of different doses of kaempferol on D‑GalN/LPS‑induced ALF depend on the autophagy pathway.Molecular medicine reports · 2021Article
- Review
- Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review.European journal of pharmacology · 2021Review
- Transcriptomic analysis of COVID‑19 lungs and bronchoalveolar lavage fluid samples reveals predominant B cell activation responses to infection.International journal of molecular medicine · 2020Article
- Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review).International journal of molecular medicine · 2020Review
- Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.Autoimmunity reviews · 2020Review
- Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.Molecular medicine reports · 2019Article
- Pyrimidine 2,4-Diones in the Design of New HIV RT Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- Bioinformatics analysis of microRNA expression between patients with and without latent tuberculosis infections.Experimental and therapeutic medicine · 2019Article
- The role of miRNAs in the invasion and metastasis of cervical cancer.Bioscience reports · 2019Review
- miR‑16‑2‑3p inhibits cell proliferation and migration and induces apoptosis by targeting PDPK1 in maxillary primordium mesenchymal cells.International journal of molecular medicine · 2019Article
- Botulinum toxin type A induces protective autophagy in human dermal microvascular endothelial cells exposed to anExperimental and therapeutic medicine · 2018Article
- Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells.Experimental and therapeutic medicine · 2018Article
- Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis.Oncotarget · 2018Article
Corrections and comments
- Erratum issuedLamenta, C [corrected to Lapenta, C]
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The capacity of the immunomodulatory drug rapamycin (RAPA) to inhibit replication of the CCR5 strain of human immunodeficiency virus (HIV) in vitro prompted us to test its effects in a murine preclinical model of HIV infection. RAPA (0.6 or 6 mg/kg body weight) or its vehicle were administered daily, per os, to SCID mice reconstituted with human peripheral blood leucocytes (hu-PBL) starting 2 days before the intraperitoneal challenge with the R5 tropic SF162 strain of HIV-1 (1000 50% tissue culture infective dose/ml). Relative to hu-PBL-SCID mice that received no treatment, HIV-infected hu-PBL-SCID mice treated with the vehicle control for 3 weeks exhibited a severe depletion of CD4(+) cells (90%), an increase in CD8(+) cells and an inversion of the CD4(+)/CD8(+) cell ratio. In contrast, treatment of HIV-infected mice with RAPA prevented a decrease in CD4(+) cells and the increase of CD8(+) cells, thereby preserving the original CD4(+):CD8(+) cell ratio. Viral infection also resulted in the detection of HIV-DNA within peritoneal cells and spleen, and lymph node tissues of the vehicle-treated mice within 3 weeks of the viral challenge. In contrast, treatment with RAPA decreased cellular provirus integration and reduced HIV-RNA levels in the blood. Furthermore, in co-cultivation assays, spleens from RAPA-treated mice exhibited a reduced capacity for infecting allogeneic T cells which was dose-dependent. These data show that RAPA possesses powerful anti-viral activity against R5 strains of HIV in vivo and support the use of additional studies to evaluate the potential application of this drug in the management of HIV patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.